Ryuvidine

CAS No. 265312-55-8

Ryuvidine ( SPS8I-2 )

Catalog No. M13813 CAS No. 265312-55-8

Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ryuvidine
  • Note
    Research use only, not for human use.
  • Brief Description
    Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).
  • Description
    Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM); shows potent cytototoxic activity against HL-60, A549, Col 1, HepG2 cancer cell lines with IC50 of 0.3-1.2 ug/mL; also inhibits SETD8 with IC50 of 0.5 uM, efficiently and selectively suppresses cellular H4K20me1 at doses lower than 5 uM.
  • Synonyms
    SPS8I-2
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    265312-55-8
  • Formula Weight
    284.30
  • Molecular Formula
    C15H12N2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1=NC2=C(C(C=C(NC3=CC=C(C)C=C3)C2=O)=O)S1
  • Chemical Name
    2-methyl-5-[(4-methylphenyl)amino]-4,7-benzothiazoledione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Blum G, et al. ACS Chem Biol. 2014 Nov 21;9(11):2471-8.
2. Ryu CK, et al. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4.
3. Lang E, et al. Cell Physiol Biochem. 2015;37(3):1178-86.
molnova catalog
related products
  • BMS-265246

    BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM in a cell-free assay.

  • HSD992

    HSD992 is a potent, selective CDK2/3 inhibitor with moderate CDK9 inhibition with IC50 of 18 nM, 57 nM and 49 nM for CDK3/cyclin E, CDK2/cyclin A1 and CDK2/cyclin E, respecively.

  • Ro-3306

    Ro-3306 is a potent, selective, ATP-competitive CDK1 inhibitor with Ki of 35 nM against CDK1/cyclin B1, 10-fold selectivity relative to CDK2/cyclin E and >50-fold relative to CDK4/cyclin D.